tetano
Editor, Senior Moderator
J Immunol
. 2020 Jun 26;ji2000583.
doi: 10.4049/jimmunol.2000583. Online ahead of print.
A Potently Neutralizing Antibody Protects Mice Against SARS-CoV-2 Infection
Wafaa B Alsoussi[SUP] 1 [/SUP], Jackson S Turner[SUP] 1 [/SUP], James B Case[SUP] 2 [/SUP], Haiyan Zhao[SUP] 1 [/SUP], Aaron J Schmitz[SUP] 1 [/SUP], Julian Q Zhou[SUP] 3 [/SUP], Rita E Chen[SUP] 2 [/SUP], Tingting Lei[SUP] 1 [/SUP], Amena A Rizk[SUP] 1 [/SUP], Katherine M McIntire[SUP] 1 [/SUP], Emma S Winkler[SUP] 1 2 [/SUP], Julie M Fox[SUP] 2 [/SUP], Natasha M Kafai[SUP] 1 2 [/SUP], Larissa B Thackray[SUP] 2 [/SUP], Ahmed O Hassan[SUP] 2 [/SUP], Fatima Amanat[SUP] 4 5 [/SUP], Florian Krammer[SUP] 4 [/SUP], Corey T Watson[SUP] 6 [/SUP], Steven H Kleinstein[SUP] 3 7 8 [/SUP], Daved H Fremont[SUP] 1 9 10 [/SUP], Michael S Diamond[SUP] 1 2 9 11 [/SUP], Ali H Ellebedy[SUP] 12 9 11 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for millions of infections and hundreds of thousands of deaths globally. There are no widely available licensed therapeutics against SARS-CoV-2, highlighting an urgent need for effective interventions. The virus enters host cells through binding of a receptor-binding domain within its trimeric spike glycoprotein to human angiotensin-converting enzyme 2. In this article, we describe the generation and characterization of a panel of murine mAbs directed against the receptor-binding domain. One mAb, 2B04, neutralized wild-type SARS-CoV-2 in vitro with remarkable potency (half-maximal inhibitory concentration of <2 ng/ml). In a murine model of SARS-CoV-2 infection, 2B04 protected challenged animals from weight loss, reduced lung viral load, and blocked systemic dissemination. Thus, 2B04 is a promising candidate for an effective antiviral that can be used to prevent SARS-CoV-2 infection.
. 2020 Jun 26;ji2000583.
doi: 10.4049/jimmunol.2000583. Online ahead of print.
A Potently Neutralizing Antibody Protects Mice Against SARS-CoV-2 Infection
Wafaa B Alsoussi[SUP] 1 [/SUP], Jackson S Turner[SUP] 1 [/SUP], James B Case[SUP] 2 [/SUP], Haiyan Zhao[SUP] 1 [/SUP], Aaron J Schmitz[SUP] 1 [/SUP], Julian Q Zhou[SUP] 3 [/SUP], Rita E Chen[SUP] 2 [/SUP], Tingting Lei[SUP] 1 [/SUP], Amena A Rizk[SUP] 1 [/SUP], Katherine M McIntire[SUP] 1 [/SUP], Emma S Winkler[SUP] 1 2 [/SUP], Julie M Fox[SUP] 2 [/SUP], Natasha M Kafai[SUP] 1 2 [/SUP], Larissa B Thackray[SUP] 2 [/SUP], Ahmed O Hassan[SUP] 2 [/SUP], Fatima Amanat[SUP] 4 5 [/SUP], Florian Krammer[SUP] 4 [/SUP], Corey T Watson[SUP] 6 [/SUP], Steven H Kleinstein[SUP] 3 7 8 [/SUP], Daved H Fremont[SUP] 1 9 10 [/SUP], Michael S Diamond[SUP] 1 2 9 11 [/SUP], Ali H Ellebedy[SUP] 12 9 11 [/SUP]
Affiliations
- PMID: 32591393
- DOI: 10.4049/jimmunol.2000583
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for millions of infections and hundreds of thousands of deaths globally. There are no widely available licensed therapeutics against SARS-CoV-2, highlighting an urgent need for effective interventions. The virus enters host cells through binding of a receptor-binding domain within its trimeric spike glycoprotein to human angiotensin-converting enzyme 2. In this article, we describe the generation and characterization of a panel of murine mAbs directed against the receptor-binding domain. One mAb, 2B04, neutralized wild-type SARS-CoV-2 in vitro with remarkable potency (half-maximal inhibitory concentration of <2 ng/ml). In a murine model of SARS-CoV-2 infection, 2B04 protected challenged animals from weight loss, reduced lung viral load, and blocked systemic dissemination. Thus, 2B04 is a promising candidate for an effective antiviral that can be used to prevent SARS-CoV-2 infection.